Opinions

Danesh Rohinton Edwards Lifesciences Corp EW-N COMMENT Jul 25, 2024

Down 30% today, the worst single-day drop since 2000. Very punishing.

The interesting is that it's still at 25x post-drop. You're seeing earnings misses get punished because the aggregate multiple they trade at is still on the high end.

Danesh Rohinton

Unknown

Unlock Rating

$59.700

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

TOP PICK

Trans-catheter aortic valve replacement is their business, a best in class valve that's been taken up widely in hospitals around the world. This market will double in three years, and they are the big player. (Analysts' target of $142.80)

DON'T BUY

When it came down to his model price it was the only buying opportunity there was in the last eight years. He loves the company. Model price is $99.94, a 30% premium that it is trading at. He can only wish for a pull back.

PAST TOP PICK

(A Top Pick Feb 08/18, Up 37%) A high-quality holding, who's business is less evasive surgery technology. They have massive market share in the space. Lots of spending by hospitals will go into this. You have to accept it will be volatile at times.

PAST TOP PICK

(A Top Pick Mar 19/18, Up 22%) He owns this through the IHI ETF. Their catheter device accounts for 60% of revenue and results in less-invasive surgeries which results in higher patient turnover in hospitals (which are expensive). This is better for patients and hospitals. They continue to take market share.

COMMENT

He has owned IRTC-O in the past. It is in the medical device space and has equipment that looks for heart arrhythmia and loads the data to the cloud. The market has not yet said this stock has taken a positive turn yet. Earnings are growing and it is growing into its share price. He wants to see it break above $85-$87 before getting back in. He would prefer holding EW-N

BUY ON WEAKNESS

It's a reopening play and the stock is down, more reason to pick it up.

DON'T BUY

Structural heart disease drugs. Must distinguish between quality stocks. This is one. However, it is less attractive due to the valuation. Future success is already priced in.

BUY

Reported a solid quarter and guidance in last April. Is up 20% YTD, but has more room to run. He's bullish medical devices.

DON'T BUY

That had a terrible quarter. They must do better.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Danesh Rohinton Edwards Lifesciences Corp EW-N COMMENT Jul 25, 2024

You might be interested:

Edwards Lifesciences Corp(EW-N)

Edwards Lifesciences Corp(EW-N)

Edwards Lifesciences Corp(EW-N)

Edwards Lifesciences Corp(EW-N)

Edwards Lifesciences Corp(EW-N)

Edwards Lifesciences Corp(EW-N)

Edwards Lifesciences Corp(EW-N)

Edwards Lifesciences Corp(EW-N)

Edwards Lifesciences Corp(EW-N)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Brendan Caldwell

The Panic-Proof Portfolio (Stockchase Research)

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase Insights

Jim Cramer - Mad Money